DiaMedica Therapeutics Announces 2018 Financial Results and Provides Corporate Update – Nasdaq
DiaMedica Therapeutics Announces 2018 Financial Results and Provides Corporate Update Nasdaq Dosed first patients in Phase Ib study of DM199 in Chronic Kidney Disease patients under an IND accepted by the FDA in 2018; Plan to initiate Phase. … Continue reading →
